Abstract 1327
Background
Oxaliplatin is frequently used in the treatment of gastrointestinal cancer patients. A known side effect of oxaliplatin administration via a peripheral vein is infusion-related pain. In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 ml glucose 5% in 2 hours).
Methods
As of December 2017, all patients treated with oxaliplatin at the Jeroen Bosch Hospital in the Netherlands received simultaneous FI. We retrospectively defined two cohorts: Patients treated with oxaliplatin and simultaneous intravenous FI starting treatment between January and November 2018, and the same number of patients treated without FI between January and November 2017. The incidence of infusion-related venous pain was the primary outcome measure. Secondary outcomes included: Incidence of hypersensitivity reactions, infusion time, dose density, the number of patients switched to a central venous catheter and the incidence of peripheral neuropathy. Chi-square tests for categorical variables and T- tests for continuous variables were used. To identify possible confounders, we conducted a multivariate logistic regression analysis.
Results
100 patients were included: 50 patients in the FI group, 50 patients in the group treated without FI. Baseline characteristics were comparable, except for age (median 66.8 versus 62.4 years in groups with and without FI; p = 0.017), and BMI (28.0 versus 25.7 kg/m2 respectively; p = 0.012). Patients treated with simultaneous FI experienced significantly less vascular pain compared to those without FI (10% versus 78% respectively (p < 0.0001; OR 0.031 (95% CI: 0.01-0.098)). No difference was observed in dose density, treatment delay, or the need of central venous catheter. Multi-variate regression analysis showed no confounders affecting the primary outcome. No adverse events of FI were observed.
Conclusions
Concurrent infusion of 800ml glucose 5% with peripheral venous administration of oxaliplatin significantly reduces the incidence of infusion-related pain in gastrointestinal cancer patients and is highly feasible and affordable in every-day clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract
5638 - Incidence of Vascular Thromboembolism Events in Cancer Patients Receiving Immunotherapy: A Single Institution Experience.
Presenter: Laura Gutiérrez Sainz
Session: Poster Display session 1
Resources:
Abstract
5182 - High Incidence of Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma.
Presenter: Alaa Abufara
Session: Poster Display session 1
Resources:
Abstract
1504 - Weight Loss over Time in Non-Small Cell Lung Cancer: Results from a Landmark Analysis of 800+ Prospectively-Treated Patients
Presenter: Jennifer Le-rademacher
Session: Poster Display session 1
Resources:
Abstract
3972 - The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC).
Presenter: Salvatore Paiella
Session: Poster Display session 1
Resources:
Abstract
2313 - Impact of Timing and Technique of Gastrostomy Placement on the Outcome of Patients (pts) with Head and Neck Cancer (HNC)
Presenter: M Julia Lostes Bardaji
Session: Poster Display session 1
Resources:
Abstract
5219 - Clinical & nutritional determinants of quality of life in patients with incurable cancer
Presenter: Louise Daly
Session: Poster Display session 1
Resources:
Abstract
4075 - Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer
Presenter: In Gyu Hwang
Session: Poster Display session 1
Resources:
Abstract
4159 - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).
Presenter: Ilaria Trestini
Session: Poster Display session 1
Resources:
Abstract
1210 - Sarcopenia and pretreatment anemia as prognostic factors for patients with localized muscle invasive bladder cancer treated by neoadjuvant chemotherapy and radical cystectomy
Presenter: Emilien Billon
Session: Poster Display session 1
Resources:
Abstract